| Symbol | BDSX |
|---|---|
| Name | BIODESIX INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Services-Medical Laboratories |
| Address | 919 WEST DILLON ROAD, LOUISVILLE, CO 80027 |
| Telephone | 303-417-0500 |
| Fax | — |
| — | |
| Website | https://www.biodesix.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001439725 |
| Description | Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. Additional info from NASDAQ: |
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
Read morePATIENCE JOHN 🟡 adjusted position in 0 shares (1 derivative) of BIODESIX INC (BDSX) Transaction Date: Jun 30, 2026 | Filing ID: 003146
Read moreNew Form EFFECT - BIODESIX INC <b>Filed:</b> 2026-05-29 <b>AccNo:</b> 9999999995-26-001816 <b>Size:</b> 1 KB
Read moreNew Form SCHEDULE 13G/A - BIODESIX INC <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001193125-26-226566 <b>Size:</b> 14 KB
Read moreBiodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
Read moreNew Form SCHEDULE 13G/A - BIODESIX INC <b>Filed:</b> 2026-05-08 <b>AccNo:</b> 0001213900-26-053983 <b>Size:</b> 19 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06728319 | A Multicenter, Retrospective, Chart Review Study Evaluating the Impact and Util… | — | Lung Nodules | Active_Not_Recruiting | 2024-09-19 | 2027-07-31 | ClinicalTrials.gov |
| NCT04676386 | Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD… | — | NSCLC Stage IV | Terminated | 2021-02-01 | 2023-12-30 | ClinicalTrials.gov |
| NCT04171492 | Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodul… | — | Nodule Solitary Pulmonary | Active_Not_Recruiting | 2020-12-18 | 2026-12-01 | ClinicalTrials.gov |
| NCT04100330 | A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or R… | Phase2 | Acute Myeloid Leukemia | Withdrawn | 2020-01-31 | 2020-03-27 | ClinicalTrials.gov |
| NCT03951012 | Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicitie… | — | Non Small Cell Lung Cancer | Terminated | 2019-04-15 | 2023-09-08 | ClinicalTrials.gov |
| NCT03766958 | A Registry to Evaluate the Performance of the BDX-XL2 Test | — | Nodule Solitary Pulmonary | Completed | 2018-10-16 | 2024-05-23 | ClinicalTrials.gov |
| NCT03289780 | Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immun… | — | Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2016-04-04 | 2025-12-01 | ClinicalTrials.gov |
| NCT02318368 | A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in S… | Phase2 | Non-small Cell Lung Cancer | Terminated | 2014-11-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT01652469 | Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Reg… | Phase3 | Carcinoma, Non-Small-Cell Lung | Completed | 2012-08-01 | 2015-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | WITHDRAWN | NCT04100330 |
| Ficlatuzumab | Other | Phase PHASE2 | Acute Myeloid Leukemia | WITHDRAWN | NCT04100330 |
| placebo | Other | Phase PHASE2 | Non-small Cell Lung Cancer | TERMINATED | NCT02318368 |
| Erlotinib | Other | Phase PHASE2 | Non-small Cell Lung Cancer | TERMINATED | NCT02318368 |
| Ficlatuzumab | Other | Phase PHASE2 | Non-small Cell Lung Cancer | TERMINATED | NCT02318368 |
| Docetaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT01652469 |
| Erlotinib | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT01652469 |
| Blood draw | Other | Preclinical | Non Small Cell Lung Cancer | TERMINATED | NCT03951012 |
| Primary Immune Response (PIR) test by Biodesix, Inc. | Other | Preclinical | NSCLC Stage IV | TERMINATED | NCT04676386 |
| Cytarabine | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | WITHDRAWN | NCT04100330 |
| Blood draw | PROCEDURE | Preclinical | Non Small Cell Lung Cancer | TERMINATED | NCT03951012 |
| placebo | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer | TERMINATED | NCT02318368 |
| Ficlatuzumab | BIOLOGICAL | Phase PHASE2 | Acute Myeloid Leukemia | WITHDRAWN | NCT04100330 |
| Docetaxel | DRUG | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT01652469 |
| Erlotinib | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer | TERMINATED | NCT02318368 |